University of Groningen

Glaucoma Considered as an Imbalance Between Production and Clearance of Neurotoxins

Wostyn, Peter; De Groot, Veva; Van Dam, Debby; Audenaert, Kurt; Killer, Hanspeter Esriel; De Deyn, Peter Paul

Published in:
Investigative ophthalmology & visual science

DOI:
[10.1167/iovs.14-15041](https://doi.org/10.1167/iovs.14-15041)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2014

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Wostyn, P., De Groot, V., Van Dam, D., Audenaert, K., Killer, H. E., & De Deyn, P. P. (2014). Glaucoma Considered as an Imbalance Between Production and Clearance of Neurotoxins. *Investigative ophthalmology & visual science*, 55(8), 5351-5352. <https://doi.org/10.1167/iovs.14-15041>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Glaucoma Considered as an Imbalance Between Production and Clearance of Neurotoxins

We read with great interest the paper by Yang et al.¹ titled "Optic Neuropathy Induced by Experimentally Reduced Cerebrospinal Fluid Pressure in Monkeys" published recently in *Investigative Ophthalmology & Visual Science*. We are grateful to the authors for sharing their findings with the scientific community, and we appreciate the opportunity to comment on an issue raised by the authors.

To examine the influence of experimentally reduced cerebrospinal fluid (CSF) pressure on retinal nerve fiber layer (RNFL) thickness and neuroretinal rim area of the optic nerve head, Yang et al.¹ conducted a study on monkeys subjected to an implantation of a lumbar-peritoneal CSF shunt. In the study group ($n = 4$ monkeys), the shunt was opened to achieve a CSF pressure of approximately 40 mm H₂O, while the shunt remained closed in the control group ($n = 5$ monkeys). During a follow-up of 1 year, two out of the four monkeys of the active intervention group showed a progressive reduction in RNFL thickness in both of their eyes, accompanied by a significant reduction in the area and volume of the neuroretinal rim and a significant increase in the cup-to-disc area ratio. Two monkeys with artificially low CSF pressure did not develop the optic neuropathy observed in the other two monkeys, nor did any monkey of the control group. The authors emphasized that they did not examine any morphological changes in the lamina cribrosa of the monkeys, and therefore concluded that their study did not present any evidence that low CSF pressure caused glaucoma at normal levels of intraocular pressure (IOP). Their study, however, supported the concept that low CSF pressure alone may cause retinal ganglion cell injury and loss and thus that a low CSF pressure may be a risk factor in all forms of optic neuropathy including glaucoma.

The hypothesis of low CSF pressure, that is, intracranial pressure (ICP), as pathogenically important for glaucoma has attracted much attention in recent years. A growing body of evidence indicates that ICP is lower in patients with primary open-angle glaucoma and normal-tension glaucoma when compared with nonglaucomatous control subjects.²⁻⁴ These findings support the notion that the relationship between IOP and ICP may play a fundamental role in the development of glaucoma.⁵ A decreased ICP, leading to an abnormally high translamina cribrosa pressure difference (TLCPD), could result in barotraumatism induced optic nerve damage at the lamina cribrosa. Conversely, recent studies have reported that ICP is higher in patients with ocular hypertension (OHT) compared with controls, giving rise to the idea that this elevated ICP may provide a protective effect for the optic nerve by decreasing the TLCPD.^{3,6}

With regard to the potential pathogenic role of an abnormally low CSF pressure in the development of optic nerve damage, a remaining question is why two monkeys with artificially low CSF pressure from the study by Yang et al.¹ did not develop an optic neuropathy. According to the authors, one explanation could be that the absence of optic neuropathy in these animals was similar to the clinical observation of OHT, in which despite elevated IOP an optic nerve damage does not develop.¹ In other words, some of the protective factors for OHT may also operate in these two monkeys. This is completely in line with the viewpoint presented in a paper by our group that is being prepared for publication (Wostyn P, et al., manuscript in preparation, 2014). In this opinion article, based on current literature, we postulate

that enhanced CSF turnover and clearance may protect against elevated IOP. Previous findings at least suggest that high IOP may generate neurotoxins that could then be cleared via the CSF.⁷⁻¹³ β -amyloid (A β) accumulation, one of the key histopathologic findings in Alzheimer's disease (AD), has been reported to increase by chronic elevation of IOP in animals with experimentally induced OHT and to cause retinal ganglion cell death, pointing to similarities in molecular cell death mechanisms between glaucoma and AD.^{7,8} On the other hand, previous studies investigating the flow of fluids in the anterior part of the optic nerve demonstrated that the fluids from the vitreous body and the optic nerve move from opposite directions and converge at the optic nerve head.^{9,10} Indeed, first of all, several studies found that there is a backward bulk flow of fluid from the vitreous into the optic nerve head.⁹⁻¹¹ In addition, several studies established that there is a flow of fluid from the subarachnoid space of the optic nerve into the optic nerve and optic nerve head.^{9,10,12,13} This at least suggests that the optic nerve subarachnoid CSF exchanges with its interstitial fluid compartment, which may facilitate clearance of interstitial solutes, including A β . Given the upregulation of A β and other putative neurotoxins after IOP elevation, rapid CSF production and hence faster CSF circulation could exert protective effects against glaucoma. This might explain the higher CSF pressure reported in subjects with OHT,^{3,6} given that the CSF pressure is the resultant of the production and outflow of CSF. Our viewpoint argues that glaucoma, just like AD, may occur when there is an imbalance between production and clearance of neurotoxins, including A β . If indeed CSF is involved in the clearance of solutes and wastes from the optic nerve, then strategies to improve CSF flow could provide a new therapeutic approach in glaucoma. This view seems to be supported by the findings from the study by Yang et al.¹ Indeed, a possible explanation for the absence of optic neuropathy in two monkeys with artificially low CSF pressure could be altered CSF dynamics related to shunt placement, that is, increased CSF flow from the ventricles, leading to enhanced removal of potentially neurotoxic waste products that accumulate in the optic nerve. Although the reduction in CSF pressure by the lumbar-peritoneal CSF shunt may increase the risk of developing optic neuropathy, shunt placement may also have a protective effect due to increased CSF turnover and clearance. We believe that this may explain why two monkeys with artificially low CSF pressure did not develop an optic neuropathy.

Peter Wostyn¹
Veva De Groot²
Debby Van Dam³
Kurt Audenaert⁴
Hanspeter Esriel Killer⁵
Peter Paul De Deyn^{3,6,7}

¹Department of Psychiatry, PC Sint-Amandus, Beernem, Belgium; ²Department of Ophthalmology, Antwerp University Hospital, Antwerp, Belgium; ³Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Department of Biomedical Sciences, Antwerp, Belgium; ⁴Department of Psychiatry, Ghent University Hospital, Ghent, Belgium; ⁵Department of Ophthalmology, Kantonsspital Aarau, Aarau, Switzerland; ⁶Department of Neurology and Memory Clinic, Middelheim General Hospital (ZNA), Antwerp, Belgium; and the ⁷Department of Neurology and Alzheimer Research Center, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
E-mail: wostyn.peter@skynet.be

References

1. Yang D, Fu J, Hou R, et al. Optic neuropathy induced by experimentally reduced cerebrospinal fluid pressure in monkeys. *Invest Ophthalmol Vis Sci*. 2014;55:3067-3073.
2. Berdahl JP, Allingham RR, Johnson DH. Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma. *Ophthalmology*. 2008;115:763-768.
3. Berdahl JP, Fautsch MP, Stinnett SS, Allingham RR. Intracranial pressure in primary open angle glaucoma, normal tension glaucoma, and ocular hypertension: a case-control study. *Invest Ophthalmol Vis Sci*. 2008;49:5412-5418.
4. Ren R, Jonas JB, Tian G, et al. Cerebrospinal fluid pressure in glaucoma: a prospective study. *Ophthalmology*. 2010;117:259-266.
5. Berdahl JP, Allingham RR. Intracranial pressure and glaucoma. *Curr Opin Ophthalmol*. 2010;21:106-111.
6. Ren R, Zhang X, Wang N, Li B, Tian G, Jonas JB. Cerebrospinal fluid pressure in ocular hypertension. *Acta Ophthalmol*. 2011;89:142-148.
7. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. *Invest Ophthalmol Vis Sci*. 2002;43:1077-1087.
8. Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. *Proc Natl Acad Sci U S A*. 2007;104:13444-13449.
9. Hayreh SS. Fluids in the anterior part of the optic nerve in health and disease. *Surv Ophthalmol*. 1978;23:1-25.
10. Rodriguez-Peralta LA. Hematic and fluid barriers in the optic nerve. *J Comp Neurol*. 1966;126:109-121.
11. Peyman GA, Apple D. Peroxidase diffusion processes in the optic nerve. *Arch Ophthalmol*. 1972;88:650-654.
12. Tsukahara I, Yamashita H. An electron microscopic study on the blood-optic nerve and fluid-optic nerve barrier. *Albrecht Von Graefes Arch Klin Exp Ophthalmol*. 1975;196:239-246.
13. Hayreh SS. Optic disc edema in raised intracranial pressure. V. Pathogenesis. *Arch Ophthalmol*. 1977;95:1553-1565.

Citation: *Invest Ophthalmol Vis Sci*. 2014;55:5351-5352.
doi:10.1167/iovs.14-15041